Profile picture for Janet Pope, MD, MPH, FRCPC

Janet Pope, MD, MPH, FRCPC

Dr. Janet Pope is a Professor of Medicine in the Division of Rheumatology at the University of Western Ontario (UWO), Schulich School of Medicine, London, Ontario, Canada.  She is the Division Head in Rheumatology at St. Joseph's Health Centre, London. Her research includes studies in scleroderma, SLE and RA, including outcome measurements, clinical trials and disease manifestations. She has published over 450 peer-reviewed articles, 15 chapters, 500 abstracts and several Cochrane meta-analysis reviews. Mentoring of research students and trainees numbers more than 125. She has received the Distinguished Investigator Award from the Canadian Rheumatology Association, Rheumatologist of the Year from the Ontario Rheumatology Association, Department of Medicine Research Achievement Award, and the Dean’s Award of Excellence in Research. She has been inducted into the Canadian Academy of Health Sciences.

 

Articles By Janet Pope, MD, MPH, FRCPC

question-mark-1872634_640.jpg

JAKi in inflammatory myositis?

By Janet Pope, MD, MPH, FRCPC

Abstract 1731 is a small RCT of baricitinib in inflammatory myositis comparing early start baricitinib to later start.

Read Article
question mark

Are Emulation Trials a Fantasy?

By Janet Pope, MD, MPH, FRCPC

Are emulation ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)?

Read Article
JAK Janus

New indications for JAK inhibitors

By Janet Pope, MD, MPH, FRCPC

There are several new positive RCTs for JAK inhibitors. Here is a summary of trials and new indications for JAKi in GCA, pediatrics, GI, dermatology and more.

Read Article
older woman with clasped hands

ICYMI: Who gives a ‘JAK’ why and how they work, as long as they do!

By Janet Pope, MD, MPH, FRCPC

Several abstracts have studied the mechanism of action of JAK inhibitors (JAKi) in various diseases. JAKi alter many other mediators affected by the JAK STAT pathway. For instance, T cell signature in blood that is proliferative was associated with a response in RA.

Read Article
puzzle.RA_.jpg

Here’s what will change my practice in Rheumatoid Arthritis

By Janet Pope, MD, MPH, FRCPC

Here's what I learned at ACR23 that will change the way I practice in rheumatoid arthritis. 

Read Article
Choices

JAKi and TYK2i: What to use and when?

By Janet Pope, MD, MPH, FRCPC

You can see that the JAKi/TYK2i have both approved or potential seropositive and seronegative indications. There are also improvements in PsO for the class and studies in CTDs. So, it is difficult to know which to choose.

Read Article
older woman with clasped hands

Who gives a ‘JAK’ why and how they work, as long as they do!

By Janet Pope, MD, MPH, FRCPC

Several abstracts have studied the mechanism of action of JAK inhibitors (JAKi) in various diseases. JAKi alter many other mediators affected by the JAK STAT pathway. For instance, T cell signature in blood that is proliferative was associated with a response in RA.

Read Article
question-mark-1872634_640.jpg

Combining a Tyk2 inhibitor with a JAKi in RA?

By Janet Pope, MD, MPH, FRCPC

At EULAR 2023, there was a late breaking abstract that compared difficult to treat patients with RA who had received treatment (including TNFi and JAKi in some patients) previously and still had active disease.

Read Article
takayasu.jpg

New treatment for Takayasu’s arteritis?

By Janet Pope, MD, MPH, FRCPC

Several studies were reported at EULAR2023 about Takayasu’s arteritis (vasculitis), a very rare large vessel vasculitis that occurs in young individuals.

Read Article
lupus_0.jpg

The future of lupus treatment is oral therapies?

By Janet Pope, MD, MPH, FRCPC

There has been an explosion of trials in SLE, including nonrenal and glomerulonephritis studies. But, what about the JAKis and Tyk2 oral drugs in SLE?

Read Article
×